Aperio Group’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $27M | Sell |
586,352
-124,781
| -18% | -$5.73M | 0.08% | 244 |
|
|
2020
Q3 | $33.5M | Sell |
711,133
-73,138
| -9% | -$3.66M | 0.11% | 174 |
|
|
2020
Q2 | $40M | Sell |
784,271
-12,383
| -2% | -$635K | 0.15% | 134 |
|
|
2020
Q1 | $37.7M | Sell |
796,654
-90,936
| -10% | -$4.85M | 0.17% | 119 |
|
|
2019
Q4 | $52.1M | Buy |
887,590
+45,913
| +5% | +$2.55M | 0.19% | 107 |
|
|
2019
Q3 | $44.9M | Buy |
841,677
+71,636
| +9% | +$3.69M | 0.18% | 118 |
|
|
2019
Q2 | $38.5M | Buy |
770,041
+55,996
| +8% | +$2.81M | 0.16% | 135 |
|
|
2019
Q1 | $37.3M | Buy |
714,045
+114,544
| +19% | +$5.72M | 0.16% | 136 |
|
|
2018
Q4 | $28.6M | Sell |
599,501
-36,348
| -6% | -$1.79M | 0.14% | 152 |
|
|
2018
Q3 | $31.9M | Buy |
635,849
+1,281
| +0.2% | +$65.1K | 0.14% | 159 |
|
|
2018
Q2 | $32M | Buy |
634,568
+110,597
| +21% | +$5.57M | 0.15% | 152 |
|
|
2018
Q1 | $25.6M | Buy |
523,971
+195,176
| +59% | +$9.09M | 0.13% | 189 |
|
|
2017
Q4 | $14.6M | Sell |
328,795
-58,390
| -15% | -$2.7M | 0.07% | 311 |
|
|
2017
Q3 | $19.6M | Sell |
387,185
-10,941
| -3% | -$555K | 0.11% | 218 |
|
|
2017
Q2 | $21.5M | Buy |
398,126
+55,316
| +16% | +$2.95M | 0.13% | 186 |
|
|
2017
Q1 | $18.1M | Buy |
342,810
+55,431
| +19% | +$2.81M | 0.12% | 195 |
|
|
2016
Q4 | $13.8M | Sell |
287,379
-190,703
| -40% | -$9.42M | 0.11% | 222 |
|
|
2016
Q3 | $25.8M | Buy |
478,082
+37,914
| +9% | +$2.08M | 0.19% | 118 |
|
|
2016
Q2 | $23.8M | Sell |
440,168
-18,892
| -4% | -$995K | 0.19% | 124 |
|
|
2016
Q1 | $23.3M | Buy |
459,060
+18,393
| +4% | +$916K | 0.2% | 120 |
|
|
2015
Q4 | $22.2M | Sell |
440,667
-2,990
| -0.7% | -$152K | 0.2% | 114 |
|
|
2015
Q3 | $21.3M | Buy |
443,657
+118,071
| +36% | +$6.15M | 0.22% | 111 |
|
|
2015
Q2 | $17M | Sell |
325,586
-56,407
| -15% | -$3.18M | 0.18% | 141 |
|
|
2015
Q1 | $22M | Buy |
381,993
+72,903
| +24% | +$4.18M | 0.25% | 91 |
|
|
2014
Q4 | $16.5M | Buy |
309,090
+44,092
| +17% | +$2.47M | 0.2% | 116 |
|
|
2014
Q3 | $15.2M | Sell |
264,998
-72,993
| -22% | -$4.47M | 0.21% | 115 |
|
|
2014
Q2 | $22.6M | Buy |
337,991
+13,973
| +4% | +$946K | 0.33% | 59 |
|
|
2014
Q1 | $21.6M | Buy |
+324,018
| New | +$21.9M | 0.3% | 57 |
|
|
2013
Q4 | – | Sell |
-268,295
| Closed | -$17.4M | – | 57 |
|
|
2013
Q3 | $16.8M | Buy |
268,295
+42,294
| +19% | +$2.72M | 0.32% | 52 |
|
|
2013
Q2 | $14.1M | Buy |
+226,001
| New | +$14.3M | 0.34% | 48 |
|
Other funds holding GSK
BCIM
Aperio Group's GSK Position: Q4 2020 in Review
Aperio Group reduced its GSK (GSK) stake by 18% in Q4 2020, selling an estimated $5.73M and leaving 586,352 shares worth $27M. The position accounts for 0.08% of the portfolio, ranked #244.
Aperio Group first reported a position in GSK in Q2 2013 and has held it in 30 quarters since. The position peaked at $52.1M in Q4 2019. 819 funds tracked by Wall St. Rank hold GSK as of Q4 2020.
- Aperio Group held 586,352 shares of GSK worth $27M as of Q4 2020.
- Aperio Group sold 124,781 GSK shares in Q4 2020, an estimated $5.73M.
- GSK made up 0.08% of Aperio Group's portfolio in Q4 2020, its #244 holding.
- Aperio Group first reported a position in GSK in Q2 2013 and has held it in 30 quarters since.
- Aperio Group's GSK position peaked at $52.1M in Q4 2019.
- 819 funds tracked by Wall St. Rank held GSK as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.